Symptoms of Alzheimer’s
Summary of Symptoms of Alzheimer’s
Primary Information, Benefits, Effects, and Important Facts
Scientific Information on Symptoms of Alzheimer’s
Get access to the latest nutrition research
By becoming an Examine.com Member, you'll have access to all of the latest nutrition research on over 300 supplements across over 500 different health goals, outcomes, conditions, and more.
Human Effect Matrix
The Human Effect Matrix looks at human studies (it excludes animal and in vitro studies) to tell you what supplements affect symptoms of alzheimer’s
| Grade | Level of Evidence [show legend] |
|---|---|
|
Robust research conducted with repeated double-blind clinical trials |
|
Multiple studies where at least two are double-blind and placebo controlled |
|
Single double-blind study or multiple cohort studies |
|
Uncontrolled or observational studies only |
|
Level of Evidence
?
The amount of high quality evidence. The more
evidence, the more we can trust the results.
|
Outcome |
Magnitude of effect
?
The direction and size of the supplement's impact on
each outcome. Some supplements can have an increasing effect, others have a decreasing effect, and others have no effect.
|
Consistency of research results
?
Scientific research does not always agree. HIGH or
VERY HIGH means that most of the scientific research agrees.
|
Notes |
|---|---|---|---|---|
|
|
Minor
|
Very High See all 5 studies |
Cognitive impairment that is associated with Alzheimer's appears to be significantly reduced with ginkgo supplementation.
|
|
|
|
Notable
|
- See study |
At least among nutraceuticals, Alpha-GPC appears to significantly improve cognition in persons with Alzheimer's disease at the dose of 1,200mg when taken as a daily supplement over a prolonged period of time.
|
|
|
|
Notable
|
Very High See 2 studies |
Very high dose Vitamin E supplementation in the form of α-tocopherol (2,000 IU) appears to reduce the rate of cognitive decline in persons with moderate to severe Alzheimer's Disease with a potency comparable to selegiline. Currently no research on lower (more standard) doses, and there appears to be no influence on minor AD or cognitive decline not characterized by AD.
|
|
|
|
||||
|
|
||||
|
|
||||
|
|
||||
